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OBJECTIVES: To determine patients’ views on the impact of
multiple sclerosis (MS) in terms of symptoms experienced,
impact on day-to-day functioning and overall quality of life
(QoL). METHODS: In-depth, unstructured qualitative inter-
views were conducted with MS patients recruited via the MS
Society in the UK. Thematic analysis was conducted on inter-
view transcripts to identify key impact areas. Interpretive phe-
nomenological analysis (IPA) was conducted to explore and
interpret participants’ perceptions of impact; speciﬁcally, the
meaning and importance patients ascribed to areas of impact.
RESULTS: Interviews were conducted with 35 individuals (15
males / 20 females). Patients were aged 31–75 (mean 50; SD
13.2) years with MS duration of 2–58 (mean 17.7; SD 14.2)
years. Eleven (31.4%) had relapsing-remitting MS, 10 (28.6%)
had secondary-progressive, two (5.7%) primary-progressive,
two (5.7%) benign MS and one (2.9%) progressive-relapsing.
MS-type was unknown by nine (25.7%) individuals. Key areas
of symptomatic impact reported were fatigue, pain, incontinence
and mood ﬂuctuation. Impact on memory and broader cognitive
problems were less commonly reported. Key areas of functional
impact related to physical incapacity (difﬁculty/inability walking,
difﬁculty using stairs), problems conducting/completing activities
of daily living, personal care, impact on social functioning,
sexual functioning and work life. IPA analysis revealed that the
most profound effects of symptomatic and functional problems
were experienced in relation to impact on quality of intimate and
social relationships, self-esteem, loss of identity, personal devel-
opment/fulﬁllment and fear of the future. CONCLUSION: The
interviews provided a rich source of information about the
nature of the impact of MS and the concerns of affected indi-
viduals. These data will be used to generate content for new 
MS-speciﬁc patient reported outcome scales of symptoms, 
functioning and quality of life (QoL) suitable for use in clinical
trials.
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OBJECTIVE: To conduct a systematic review of the effect of
ibandronate on bone mineral density (BMD) and fractures in
postmenopausal women (PMW). METHODS: We followed the
Cochrane collaboration methodology to identify randomized
placebo-controlled trials comparing PMW receiving ibandronate
to those not receiving ibandronate. Trials were included in our
review if they had study duration of ONE year or longer and
reported BMD or fracture incidence as outcomes. A priori
hypotheses dealing with mode and frequency of administration,
dosage, study duration and severity of osteoporosis were devel-
oped to help explain heterogeneity of treatment effects. Hetero-
geneity testing was conducted using regression models. All
analyses were performed using Comprehensive Meta-Analysis,
version 2.2, software. RESULTS: Nine trials met eligibility cri-
teria. The trials included a total of 8784 women; 6111 received
ibandronate and 2673 placebo. Study results were reported at
one, two and three years for ﬁve, two and two studies, respec-
tively. Ibandronate dose and frequency varied across studies and
all trials had > one treatment arm. In all studies, ibandronate
was found to increase BMD in the spine and hip compared to
placebo; the average increase in spine BMD was about 4% and
hip BMD about 2.75%. The BMD increase varied signiﬁcantly
by severity of osteoporosis, mode and frequency of administra-
tion, dosage, and study duration. Only two studies reported data
on fractures. In one study (Chesnut et al, JBMR 2004), iban-
dronate reduced the risk of vertebral fractures but not non-
vertebral fractures compared to placebo after three years of 
treatment. In the other study (Recker et al, Bone 2004), risk
reduction was observed for neither vertebral nor non-vertebral
fractures. CONCLUSIONS: Ibandronate appears to increase
BMD and reduces the incidence of vertebral fractures but not
non-vertebral fractures. Additional data are required to better
assess the impact of ibandronate on BMD and fractures in post-
menopausal osteoporosis.
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OBJECTIVES: Balloon kyphoplasty and vertebroplasty are
increasingly used in non-surgical management of patients with
vertebral compression fractures (VCF). To date there has been
no published systematic review that has compared the two 
procedures. METHODS: Number of electronic databases
(MEDLINE, EMBASE and Cochrane Library) were searched
through to March 1, 2004. Citation searching of included studies
and no language restrictions were applied. All controlled and
non-controlled study designs were included. Two reviewers
carried out study selection. RESULTS: Total of 4 comparative
observational studies (3 versus conventional medical manage-
ment [CMM] & 1 versus vertebroplasty) and 13 case series for
balloon kyphoplasty and 2 comparative observational studies (1
study versus kyphoplasty and one study versus CMM) and 57
case series for vertebroplasty were identiﬁed. Across studies,
majority (>80%) of VCF patients were osteoporotic, had expe-
rienced pain for an average of ﬁve to seven months and were
refractory to CMM. Compared to CMM alone, statistically sig-
niﬁcant gains in pain relief and functional improvement were
observed following both balloon kyphoplasty and vertebro-
plasty. Although the magnitude of pain relief appears to be
similar for both procedures, there is consistent evidence of sub-
stantive enhancement in quality of life following balloon kypho-
plasty, evidence that is more limited for vertebroplasty. A total
of 8% and 40% of operated vertebrae experienced cement leak-
ages following balloon kyphoplasty and vertebroplasty, respec-
tively. Unlike balloon kyphoplasty, a number of vertebroplasty
cement leakages are symptomatic (5% of patients) and a number
of serious adverse events have also been reported (e.g. neurologic
injury and pulmonary embolism). CONCLUSION: This review
demonstrates there is level III evidence to support the use of
balloon kyphoplasty and vertebroplasty in the management of
osteoporotic VCFs. Compared to vertebroplasty; balloon kypho-
plasty appears to have a superior safety proﬁle. The results from
